Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3D-PTA-guided chemotherapy + capecitabine
- Development stage
- Unknown
- Lead developer
- Fudan University Shanghai Cancer Center
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
3D-PTA-guided chemotherapy + capecitabine is an experimental personalized adjuvant treatment regimen developed by Fudan University for patients with resected stage II/III cholangiocarcinoma. The regimen involves the administration of capecitabine, an oral fluoropyrimidine carbamate prodrug of 5-fluorouracil, in combination with a specific chemotherapeutic agent (such as gemcitabine, oxaliplatin, or cisplatin) that has been identified as the most effective for the individual patient's tumor through 3D-Patient-derived Tumor Assay (3D-PTA) drug sensitivity testing. Capecitabine works by inhibiting thymidylate synthase, thereby blocking the synthesis of thymidine triphosphate and disrupting DNA replication. The addition of a 3D-PTA-selected chemotherapy agent is intended to enhance the cytotoxic effect and improve survival outcomes compared to standard capecitabine monotherapy.
- Other names
- 3D-PTA-guided chemotherapy combined with capecitabine3D-PTA susceptibility testing-guided adjuvant chemotherapy
02
Targets
DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on 3D-PTA-guided chemotherapy + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 3D-PTA-guided chemotherapy + capecitabine.